Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report)’s inventory value hit a brand new 52-week low throughout buying and selling on Tuesday after Needham & Firm LLC lowered their value goal on the inventory from $19.00 to $14.00. Needham & Firm LLC at the moment has a purchase score on the inventory. Vir Biotechnology traded as little as $4.69 and final traded at $4.70, with a quantity of 2549640 shares. The inventory had beforehand closed at $5.30.
VIR has been the topic of a number of different analysis experiences. Leerink Companions boosted their goal value on Vir Biotechnology from $18.00 to $20.00 and gave the inventory an “outperform” score in a analysis word on Monday, January thirteenth. The Goldman Sachs Group lowered their value goal on shares of Vir Biotechnology from $28.00 to $21.00 and set a “purchase” score for the corporate in a analysis word on Thursday, April seventeenth. HC Wainwright reissued a “purchase” score and issued a $110.00 value goal on shares of Vir Biotechnology in a analysis report on Friday, February twenty eighth. Lastly, Barclays boosted their value goal on shares of Vir Biotechnology from $26.00 to $31.00 and gave the corporate an “obese” score in a analysis word on Friday, February twenty eighth. One equities analysis analyst has rated the inventory with a maintain score and 6 have issued a purchase score to the corporate. Based mostly on information from MarketBeat, Vir Biotechnology at the moment has a mean score of “Reasonable Purchase” and a consensus goal value of $32.86.
Examine Out Our Newest Analysis Report on Vir Biotechnology
Insider Exercise at Vir Biotechnology
In different Vir Biotechnology information, Director George A. Scangos offered 10,964 shares of the corporate’s inventory in a transaction that occurred on Tuesday, February 18th. The inventory was offered at a mean value of $9.81, for a complete worth of $107,556.84. Following the sale, the director now owns 708,295 shares within the firm, valued at roughly $6,948,373.95. This represents a 1.52% lower of their place. The transaction was disclosed in a doc filed with the SEC, which is accessible by means of this hyperlink. Additionally, EVP Verneuil Vanina De offered 7,373 shares of the agency’s inventory in a transaction dated Wednesday, February twenty sixth. The shares had been offered at a mean value of $9.14, for a complete transaction of $67,389.22. Following the completion of the transaction, the chief vp now immediately owns 79,460 shares within the firm, valued at $726,264.40. This represents a 8.49% lower of their possession of the inventory. The disclosure for this sale could be discovered right here. Within the final three months, insiders have offered 99,611 shares of firm inventory valued at $663,525. 15.60% of the inventory is owned by company insiders.
Institutional Buyers Weigh In On Vir Biotechnology
Institutional buyers and hedge funds have lately made modifications to their positions within the inventory. Point72 Asia Singapore Pte. Ltd. bought a brand new stake in Vir Biotechnology throughout the fourth quarter value about $42,000. GAMMA Investing LLC raised its holdings in shares of Vir Biotechnology by 524.3% within the 1st quarter. GAMMA Investing LLC now owns 7,111 shares of the corporate’s inventory valued at $46,000 after buying a further 5,972 shares within the final quarter. SBI Securities Co. Ltd. bought a brand new stake in shares of Vir Biotechnology throughout the 4th quarter value $60,000. PNC Monetary Providers Group Inc. grew its stake in shares of Vir Biotechnology by 31.8% throughout the fourth quarter. PNC Monetary Providers Group Inc. now owns 8,288 shares of the corporate’s inventory value $61,000 after buying a further 1,999 shares within the final quarter. Lastly, KBC Group NV elevated its holdings in Vir Biotechnology by 136.5% within the fourth quarter. KBC Group NV now owns 8,970 shares of the corporate’s inventory valued at $66,000 after shopping for a further 5,177 shares over the last quarter. 65.32% of the inventory is owned by hedge funds and different institutional buyers.
Vir Biotechnology Value Efficiency
The inventory has a 50 day easy transferring common of $6.15 and a two-hundred day easy transferring common of $7.90. The corporate has a market capitalization of $648.90 million, a price-to-earnings ratio of -1.20 and a beta of 1.36.
Vir Biotechnology (NASDAQ:VIR – Get Free Report) final launched its quarterly earnings outcomes on Wednesday, Could seventh. The corporate reported ($0.88) EPS for the quarter, lacking the consensus estimate of ($0.83) by ($0.05). The agency had income of $3.03 million for the quarter, in comparison with analyst estimates of $8.59 million. Vir Biotechnology had a destructive return on fairness of 36.71% and a destructive web margin of 678.40%. The corporate’s quarterly income was down 94.6% on a year-over-year foundation. Throughout the identical interval final 12 months, the agency earned ($0.48) EPS. Equities analysis analysts predict that Vir Biotechnology, Inc. will submit -3.92 EPS for the present 12 months.
About Vir Biotechnology
(Get Free Report)
Vir Biotechnology, Inc, an immunology firm, develops therapeutic merchandise to deal with and stop severe infectious illnesses. Its medical improvement pipeline consists of product candidates focusing on hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The corporate’s preclinical candidates embody these focusing on influenza A and B, coronavirus illness 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
Beneficial Tales
Obtain Information & Rankings for Vir Biotechnology Day by day – Enter your e mail handle beneath to obtain a concise day by day abstract of the newest information and analysts’ scores for Vir Biotechnology and associated corporations with MarketBeat.com’s FREE day by day e mail e-newsletter.
